“Another mouth ulcer—must be all that spicy hotpot I’ve been eating. Time for some cooling herbal tea!” This common refrain reflects a widespread cultural misconception: that recurrent oral ulcers are simply the result of “heatiness” or internal imbalance. But mounting clinical evidence tells a different story—one rooted in immunology, not traditional humoral theory. In fact, the vast majority of recurrent aphthous stomatitis (RAS) cases are not caused by dietary excess or “fire” in the body. Instead, they stem from dysregulated immune responses—a critical distinction that reshapes how clinicians approach diagnosis and treatment.
Oral ulcers—clinically termed aphthae—are discrete, painful, round or oval mucosal defects characterized by a yellowish-white pseudomembranous center surrounded by an erythematous halo. They arise when the oral mucosal epithelium, a delicate yet vital barrier lining the mouth, becomes compromised. While trauma, nutritional deficiencies, or stress may act as triggers, the underlying pathophysiology in recurrent cases often involves aberrant cell-mediated immunity. Approximately 60–70% of patients with recurrent RAS exhibit T-lymphocyte–driven autoimmune activity, wherein cytotoxic T cells mistakenly target and destroy keratinocytes in the oral epithelium, leading to localized necrosis and ulcer formation.
Given this immunopathogenic basis, effective management requires a multifaceted strategy: modulating local immune activation, suppressing inflammation, alleviating pain, preventing secondary infection, and supporting epithelial regeneration. Topical therapy plays a central role—and among clinically used agents, compound chamomile-lidocaine gel (marketed as Ganmeida Gel) has demonstrated consistent efficacy across these domains.
The gel’s therapeutic profile rests on three synergistic pharmacological actions. First, its lidocaine hydrochloride component provides rapid-onset topical anesthesia by reversibly blocking voltage-gated sodium channels in sensory nerve fibers, thereby interrupting pain signal transmission within minutes of application. Second, the formulation combines chamomile tincture and thymol—two natural antimicrobial and anti-inflammatory agents. Chamomile inhibits cyclooxygenase activity, reduces prostaglandin synthesis, exerts antihistaminic effects, and demonstrates bacteriostatic activity against Staphylococcus aureus, a frequent colonizer of oral ulcers. Thymol, present at 1.0 mg/g, exhibits broad-spectrum activity against bacteria, fungi, and viruses; notably, its toxicity is only one-quarter that of phenol, making it both potent and well tolerated in oral mucosal applications. Together, these agents reduce perilesional edema, erythema, and microbial load—lowering the risk of secondary infection.
Third, emerging preclinical and clinical data indicate that the gel actively supports mucosal repair. Studies show it downregulates pro-inflammatory cytokines—including TNF-α and IL-6—at the ulcer site while enhancing expression of epidermal growth factor (EGF), a key mediator of epithelial proliferation and wound closure. Complementary research confirms that chamomile-derived compounds independently promote fibroblast migration and collagen deposition, accelerating re-epithelialization. This tripartite mechanism—analgesia, anti-inflammation, and tissue regeneration—underpins the gel’s clinical utility in managing mild-to-moderate RAS.
While compound chamomile-lidocaine gel offers robust symptomatic relief and healing support, clinicians emphasize that persistent, unusually large, or atypical ulcers warrant comprehensive evaluation. Frequent recurrence, prolonged duration (>3 weeks), or associated systemic symptoms may signal underlying conditions such as celiac disease, inflammatory bowel disease, Behçet syndrome, or hematologic disorders. Self-treatment should never replace timely specialist assessment—especially when ulcers deviate from classic clinical patterns or fail to respond to standard topical interventions.